Beyond the M‐CSF receptor – novel therapeutic targets in tumor‐associated macrophages
Citations Over TimeTop 19% of 2017 papers
Abstract
Tumor-associated macrophages (TAM) are by now established as important regulators of tumor progression by impacting on tumor immunity, angiogenesis, and metastasis. Hence, a multitude of approaches are currently pursued to intervene with TAM's protumor activities, the most advanced of which being a blockade of macrophage-colony stimulating factor (M-CSF)/M-CSF receptor (M-CSFR) signaling. M-CSFR signaling largely impacts on the differentiation of macrophages, including TAM, and hence strongly influences the numbers of these cells in tumors. However, a repolarization of TAM toward a more antitumor phenotype may be more elegant and may yield stronger effects on tumor growth. In this respect, several aspects of TAM behavior could be altered, such as their intratumoral localization, metabolism and regulatory pathways. Intervention strategies could include the use of small molecules but also new generations of biologicals which may complement the current success of immune checkpoint blockers. This review highlights current work on the search for new therapeutic targets in TAM.
Related Papers
- → Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer(2016)34 cited
- → A progressive T cell exhaustion program mapped across tissues in patients with lung cancer on immune checkpoint blockade(2023)4 cited
- → A PD-L1 Negative Advanced Gastric Cancer Patient With a Long Response to PD-1 Blockade After Failure of Systematic Treatment: A Case Report(2021)11 cited
- → Tumor organoid-originated biomarkers predict immune response to PD-1 blockade(2021)7 cited
- → Distinct immunologic changes in vivo following combination versus individual PD-1 or CTLA-4 checkpoint blockade in human cancer(2014)